RBC Capital analyst Gregory Renza maintained a Hold rating on Fusion Pharmaceuticals (FUSN – Research Report) yesterday and set a price target of $21.00. The company’s shares closed yesterday at $21.40.
According to TipRanks, Renza is a 5-star analyst with an average return of 19.2% and a 47.61% success rate. Renza covers the Healthcare sector, focusing on stocks such as Agios Pharma, ADC Therapeutics, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Fusion Pharmaceuticals with a $20.94 average price target.
The company has a one-year high of $21.58 and a one-year low of $2.31. Currently, Fusion Pharmaceuticals has an average volume of 2.06M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fusion Pharmaceuticals (FUSN) Company Description:
Fusion Pharmaceuticals Inc is a clinical stage bio-pharmaceutical company focused on developing alpha therapeutics for curing cancer.
Read More on FUSN:
- Fusion Pharmaceuticals Inc. Grapples with Tax Uncertainty: Potential Impacts on Finances and Investor Trust
- Fusion Pharmaceuticals Poised for AstraZeneca Acquisition
- Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
- Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
- Fusion Pharmaceuticals management to meet with Oppenheimer
